網民發信反對曠視科技來港上市 李小加強調有既定原則審視不受政治影響
有網民發起向港交所(00388.HK)發信反對曠視科技來港上市,市傳公司未能通過上市聆訊,港交所行政總裁李小加出席上市儀式後表示,香港上市規則十分清晰、非常有預見性,亦有極其嚴肅的原則性,因此會按既定原則及現有規則對待每一家公司,強調會不加任何歧視地進行審閱,通過了的話即使有人反對亦可以上市,不能通過的話即使有再強大的支持亦不能通過,不受政治或他人影響。
針對公司被美國列入實體清單,李小加強調該份名單非「黑名單」或「白名單」,而是美國按自己標準列出的名單,強調是按香港的標準決定是否可以上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.